ArticleCold Spring Harbor molecular case studies2018

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Jikui Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.